Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 10/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18552151 | 0.94 | KDR (0.52) | ESRRAESR1ESR2PTPN11KDM1A | |
| SCHEMBL18552051 | 0.89 | KDR (0.50) | ESRRAPTPN11KDM1AKDRHPGD | |
| SCHEMBL18552150 | 0.86 | BRD4 (0.46) | PTPN11KDM1AKDRMAPTPKM | |
| SCHEMBL18552136 | 0.86 | KDR (0.47) | ESRRAPTPN11KDM1AKDRMAPT | |
| SCHEMBL18552052 | 0.82 | ABL1 (0.44) | PTPN11KDM1AKDR | |
| SCHEMBL18552222 | 0.81 | ESR1 (0.46) | ESRRAESR1ESR2 | |
| SCHEMBL18552156 | 0.81 | ESR1 (0.46) | ESRRAESR1ESR2 | |
| SCHEMBL18551977 | 0.81 | ESR1 (0.46) | ESRRAESR1ESR2 | |
| SCHEMBL18552033 | 0.79 | ESR1 (0.42) | ESRRAESR1ESR2MAPT | |
| SCHEMBL18552223 | 0.78 | DYRK1A (0.49) | ESRRAESR1ESR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002270-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | LIGHTWAVE LOGIC, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20180044333-A1 | Tricyclic Spacer Systems for Nonlinear Optical Devices | GOETZ JENNIFER (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170204091-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR DEVICES | LIGHTWAVE LOGIC INC (US) | 2017-07-20 | — | — | US | disclosed |
| US-20140121376-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | LIGHTWAVE LOGIC, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8298326-B2 | Tricyclic spacer systems for nonlinear optical devices | GOETZ SR FREDERICK J (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110112295-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | Lightwave Logic Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7894695-B2 | Tricyclic spacer systems for nonlinear optical devices | LIGHTWAVE LOGIC, INC. | 2011-02-22 | — | — | US | disclosed |
| US-20080009620-A1 | Tricyclic Spacer Systems For Nonlinear Optical Devices | THIRD-ORDER NANOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009620-A1 | Tricyclic Spacer Systems For Nonlinear Optical Devices | AQP4, CCND3, CDK14 | ESRRA 2869/4885ESR1 925/4885ESR2 2663/4885 |
| US-20140121376-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | AQP4, CCND3, CDK14 | ESRRA 2869/4885ESR1 925/4885ESR2 2663/4885 |
| US-20170204091-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR DEVICES | CCND3, CCNY, CCND2 | ESRRA 2145/4885ESR1 729/4885ESR2 2379/4885 |
| US-20110112295-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | AQP4, CCND3, CDK14 | ESRRA 2869/4885ESR1 925/4885ESR2 2663/4885 |
| US-20210002270-A1 | TRICYCLIC SPACER SYSTEMS FOR NONLINEAR OPTICAL DEVICES | AQP4, CCND3, CDK14 | ESRRA 2869/4885ESR1 925/4885ESR2 2663/4885 |
| US-20180044333-A1 | Tricyclic Spacer Systems for Nonlinear Optical Devices | AQP4, CCND3, CDK14 | ESRRA 2869/4885ESR1 925/4885ESR2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.